AVI BioPharma Announces 2007 Second Quarter Financial Results Conference Call
August 01 2007 - 1:47PM
Business Wire
AVI BioPharma Inc. (Nasdaq:AVII) today announced that the company
will hold a conference call to discuss its 2007 second quarter
financial results on Wednesday, August 8, 2007, at 11:00 a.m.
Eastern time (8:00 a.m. Pacific time). Individuals interested in
listening to the live conference call may do so by dialing (888)
803-8271 toll free within the United States and Canada, or (706)
634-2467 for international callers. A telephone replay of the
conference call will be available for 48 hours, beginning August 8
within two hours after the conclusion of the call, by dialing (800)
642-1687 domestically, or (706) 645-9291 internationally, and
entering reservation number 7205349. The conference call can be
heard live via audio webcast at the company�s Web site:
www.avibio.com. A webcast replay will be available for 14 days.
About AVI BioPharma AVI BioPharma develops therapeutic products for
the treatment of life-threatening diseases using third-generation
NEUGENE� antisense drugs and ESPRIT exon skipping technology. AVI�s
lead NEUGENE antisense compound is designed to target cell
proliferation disorders, including cardiovascular restenosis. In
addition to targeting specific genes in the body, AVI�s antiviral
program uses NEUGENE antisense compounds to combat disease by
targeting single-stranded RNA viruses, including West Nile virus,
hepatitis C virus, dengue virus, Ebola virus and influenza A virus.
AVI�s NEUGENE-based ESPRIT technology will initially be applied to
potential treatments for Duchenne muscular dystrophy. More
information about AVI is available on the company�s Web site at
http://www.avibio.com. �Safe Harbor� Statement under the Private
Securities Litigation Reform Act of 1995: The statements that are
not historical facts contained in this release are forward-looking
statements that involve risks and uncertainties, including, but not
limited to, the results of research and development efforts, the
results of preclinical and clinical testing, the effect of
regulation by the FDA and other agencies, the impact of competitive
products, product development, commercialization and technological
difficulties, and other risks detailed in the company�s Securities
and Exchange Commission filings.
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avi Biopharma (NASDAQ:AVII)
Historical Stock Chart
From Jul 2023 to Jul 2024